04 October 2018   This is a notice regarding an individual or entity ceasing to be a substantial shareholder.    Download PDF for more

03 October 2018   CLINUVEL PHARMACEUTICALS LTD (ASX: CUV; XETRA-DAX: UR9; NASDAQ INTERNATIONAL DESIGNATION: CLVLY) today announced it will hold its 2018 Annual General Meeting of shareholders on Wednesday 21 November 2018 at 10.00am AEDT at The Events Centre at Collins Square, Tower 2, Level 6, 727 Collins Street, Melbourne, VIC 3008 Australia.   Downlaod […]

01 October 2018   CLINUVEL PHARMACEUTICALS LTD today announced that it has reached agreement with two European porphyria expert centres on a clinical trial protocol to conduct a Phase IIa proof of concept study evaluating the safety and effectiveness of SCENESSE® (afamelanotide 16mg) in variegate porphyria (VP). The study (CUV040) will start patient treatment in […]

20 September 2018 CLINUVEL PHARMACEUTICALS LTD (ASX: CUV; XETRA-DAX: UR9; NASDAQ INTERNATIONAL DESIGNATION: CLVLY) presented to the Nasdaq Virtual Investor Conference on Wednesday 19 September. A copy of the presentation is appended. Download PDF to read more

11 September 2018   New issue announcement, application for quotation of additional securities and agreement.   Download PDF to read more

10 September 2018   CLINUVEL PHARMACEUTICALS LTD (ASX: CUV; XETRA-DAX: UR9; NASDAQ INTERNATIONAL DESIGNATION: CLVLY) presented to the BioCentury NewsMakers conference in New York on Friday 07 September. A copy of the presentation and speaking notes is appended.    Download PDF for more

05 September 2018   CLINUVEL PHARMACEUTICALS LTD (ASX: CUV; XETRA-DAX: UR9; NASDAQ INTERNATIONAL DESIGNATION: CLVLY) today announced that the US Food and Drug Administration (FDA) has issued a request for further documentation to support CLINUVEL’s new drug application (NDA) for SCENESSE® (afamelanotide 16mg). This additional information covers product manufacturing information and details from the European […]

04 September 2018   Enclosed is a notice of change of interests of substantial change holders.   Download PDF for more

Download attachments: Download PDF

29 August 2018   CLINUVEL PHARMACEUTICALS LTD (ASX: CUV; XETRA-DAX: UR9; NASDAQ INTERNATIONAL DESIGNATION: CLVLY) is pleased to announce that it will issue a dividend for the first time in its history for the 12-month financial reporting period ended 30 June 2018. Subject to the Company maintaining sufficient reserves, the Board of Directors have agreed […]

29 August 2018   The Directors of the Board present their report on the Company and its controlled entities (‘Group’) for the financial year ended 30 June 2018 and the Auditor’s Independence Declaration thereon.   Download PDF to read more

21 August 2018   Increasing interest has been seen in the interaction between the human body and non-ionising radiation, part of the emerging field of photomedicine. During the latter decades of the last century the scientific community first began to grasp the short- and long-term impacts of acute and chronic exposure to invisible ultraviolet (UV) […]

30 July 2018   CLINUVEL PHARMACEUTICALS LTD (ASX: CUV; XETRA-DAX: UR9; NASDAQ INTERNATIONAL DESIGNATION: CLVLY), a global biopharmaceutical company focused on developing and delivering treatments for patients with a range of severe genetic and skin disorders, today announced its Appendix 4C – Quarterly Cashflow report for the period 01 April to 30 June 2018. All […]

27 July 2018   On 25 June 2018 CLINUVEL announced its New Drug Application (NDA) for SCENESSE® (afamelanotide 16mg) for adult erythropoietic protoporphyria (EPP) patients had been submitted to the US Food and Drug Administration (FDA). It has been imperative for our teams to thoroughly prepare the scientific write-up and analyses of the use of […]

17 July 2018 Enclosed is a notice of a change of interest of a  substantial shareholder. Download PDF for more